About Pharmazz
Pharmazz is a company based in Noida (India) founded in 2010 by Ajit Chand Srimal and Anil Gulati. Pharmazz has raised $57.02 million across 18 funding rounds from investors including Sun Pharma, HHS and Duke Fashions. The company has 37 employees as of April 07, 2024. Pharmazz operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Noida, India
- Employees 37 as on 07 Apr, 2024
- Founders Ajit Chand Srimal, Anil Gulati
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharmazz India Private Limited
- Date of Incorporation 16 Mar, 2011
- Jurisdiction New Delhi, Delhi, India
-
Annual Revenue
$918.81 K (USD)50.8as on Mar 31, 2023
-
Net Profit
$211.97 K (USD)261.02as on Mar 31, 2023
-
EBITDA
$513.81 K (USD)255.98as on Mar 31, 2023
-
Total Equity Funding
$57.02 M (USD)
in 18 rounds
-
Latest Funding Round
$250 K (USD), Series C
Jul 13, 2026
-
Investors
Sun Pharma
& 97 more
-
Employee Count
37
as on Apr 07, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Pharmazz
Unlock access to complete
Unlock access to complete
Funding Insights of Pharmazz
Pharmazz has successfully raised a total of $57.02M across 18 strategic funding rounds. The most recent funding activity was a Series C round of $250 thousand completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pharmazz
Pharmazz has secured backing from 98 investors, including institutional and angel investors. Prominent investors backing the company include Sun Pharma, HHS and Duke Fashions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Internet first brand of moderate casual wear for men and women
|
Locked | Locked | Locked |
Investor details for Pharmazz
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharmazz
Investment portfolio details for Pharmazz
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pharmazz
Detailed financials for Pharmazz
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmazz Comparisons
Peer comparison for Pharmazz
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pharmazz
Pharmazz operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of Pharmazz
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmazz
Complete news archive for Pharmazz
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmazz
Pharmazz was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Pharmazz is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.
Anil Gulati is the current CEO of Pharmazz. They have also founded this company.
Pharmazz is a funded company, having raised a total of $57.02M across 18 funding rounds to date.
As of Apr 07, 2024, the latest employee count at Pharmazz is 37.
Annual revenue of Pharmazz is $918.81K as on Mar 31, 2023.
Pharmazz is a clinical stage pharmaceutical company engaged in the development of pharmaceutical products for use in critical care and hospital settings. The company has three lead candidates, PMZ-2010 (for hypovolemic shock, cardiac arrest postoperative pain), PMZ-1620 ( for Alzheimers, ischemic stroke, spinal cord injury and tumor diagnosis) and PMZ-2123 (for opioid tolerance pain management, diabetic ketoacidosis. These molecules are in preclinical different clinical stages for different indications. The company also provides pre-clinical and clinical services to other pharmaceutical companies.
Pharmazz's top competitors include Merck, Roivant Sciences and AbbVie.
Pharmazz has 98 investors. Key investors include Sun Pharma, HHS, Duke Fashions, Univeso Integrated Solutions, and Lalit Gulati.
The valuation of Pharmazz is $38.86M as of Mar 2020.